- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT03827668
A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
18 mei 2020 bijgewerkt door: Pfizer
A PHASE I, OPEN LABEL, FIXED SEQUENCE STUDY TO EVALUATE THE STEADY STATE PHARMACOKINETIC DRUG-DRUG INTERACTION BETWEEN PF-06650833 AND PF-06651600 IN HEALTHY ADULT PARTICIPANTS
The purpose of this study is to evaluate the potential pharmacokinetic (PK) drug-drug interaction (DDI) between PF-06650833 and PF-06651600 in healthy adult participants.
Studie Overzicht
Toestand
Voltooid
Conditie
Studietype
Ingrijpend
Inschrijving (Werkelijk)
15
Fase
- Fase 1
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06511
- Pfizer New Haven Clinical Research Unit
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 55 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD)
- Male and female participants who are healthy as determined by medical evaluation including medical history, physical examination, including blood pressure (BP) and pulse rate measurement, temperature, 12-lead ECG, and laboratory tests.
- Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
- Capable of giving signed informed consent as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, dermatological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
- Known immunodeficiency disorder, including positive serology for human immunodeficiency virus (HIV) at screening, or a first degree relative with a hereditary immunodeficiency.
- Infection with hepatitis B or hepatitis C viruses according to protocol-specific testing algorithm.
- Participants with any of the protocol-listed acute or chronic infections or infection history.
- History of febrile illness within 5 days prior to the first dose of investigational product (in both Periods).
- History of any lymphoproliferative disorder such as Epstein Barr Virus (EBV) related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
- Participants have a known present or a history of malignancy other than a successfully treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- Benign ethnic (cyclic) neutropenia.
- Having received any live (attenuated) vaccines within 6 weeks prior to the first dose of investigational product.
- Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
- Previous administration of an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) preceding the first dose of investigational product used in this study.
- Known participation in a clinical trial of PF-06650833 or PF-06651600.
- A positive urine drug test at screening or admission.
- Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
- Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
- Participants with any of the protocol-listed abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary.
- Have evidence of untreated or inadequately treated active or latent Mycobacterium tuberculosis (TB) infection.
- History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
- Use of tobacco/nicotine containing products in excess of 5 cigarettes/day.
- Have a history of major organ transplant or hematopoietic stem cell/marrow transplant. Skin grafts are allowed.
- Systemic therapy with any of the medications that are CYP3A4 inhibitors within 7 days or 5 half-lives (whichever is longer) or CYP3A4 inducers within 28 days or 5 half-lives (whichever is longer) prior to the first dose of the trial medication.
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the Lifestyle Considerations criteria of the protocol.
- Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Single arm
The study will have only one study group in a fixed-sequence type of design with two periods
|
In Period 1, Days 1-5, participants will receive PF-06650833 once daily alone.
In Period 2, Days 1-7, participants will receive PF-06651600 once daily alone.
In Period 2, Days 8-12, participants will receive PF-06650833 once daily together with PF-06650833 once daily.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
PF-06650833 Cmax
Tijdsspanne: Fold-change from Period 1/Day 5 to Period 2/Day 12
|
Maximum observed concentration (Cmax) derived from plasma
|
Fold-change from Period 1/Day 5 to Period 2/Day 12
|
PF-06650833 AUCtau
Tijdsspanne: Fold-change from Period 1/Day 5 to Period 2/Day 12
|
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
|
Fold-change from Period 1/Day 5 to Period 2/Day 12
|
PF-06651600 Cmax
Tijdsspanne: Fold-change from Period 2/Day 7 to Period 2/Day 12
|
Maximum observed concentration (Cmax) derived from plasma
|
Fold-change from Period 2/Day 7 to Period 2/Day 12
|
PF-06651600 AUCtau
Tijdsspanne: Fold-change from Period 2/Day 7 to Period 2/Day 12
|
Area under the plasma concentration-time profile derived from plasma from time 0 to time tau, the dosing interval (AUCtau), where tau=24 for QD dosing.
|
Fold-change from Period 2/Day 7 to Period 2/Day 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Percentage of participants with treatment emergent adverse events
Tijdsspanne: From screening until follow-up phone call that takes place 28-35 days after last study dose (total period of approximately 87 days)
|
From screening until follow-up phone call that takes place 28-35 days after last study dose (total period of approximately 87 days)
|
Percentage of participants with clinical laboratory test results above/below certain threshold
Tijdsspanne: At screening; Days -1, 6 in Period 1; and Days -1, 8, 9, 11, 13 in Period 2
|
At screening; Days -1, 6 in Period 1; and Days -1, 8, 9, 11, 13 in Period 2
|
Percentage of participants with vital signs above/below certain threshold
Tijdsspanne: At screening; Days 1, 6 in Period 1; and Days 1, 8, 9, 12, 13 in Period 2
|
At screening; Days 1, 6 in Period 1; and Days 1, 8, 9, 12, 13 in Period 2
|
Percentage of participants with 12-lead electrocardiogram (ECG) results above/below certain threshold
Tijdsspanne: At screening; Days 1, 6 in Period 1; and Days 1, 8, 9, 12, 13 in Period 2
|
At screening; Days 1, 6 in Period 1; and Days 1, 8, 9, 12, 13 in Period 2
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
7 februari 2019
Primaire voltooiing (Werkelijk)
29 april 2019
Studie voltooiing (Werkelijk)
29 april 2019
Studieregistratiedata
Eerst ingediend
31 januari 2019
Eerst ingediend dat voldeed aan de QC-criteria
31 januari 2019
Eerst geplaatst (Werkelijk)
1 februari 2019
Updates van studierecords
Laatste update geplaatst (Werkelijk)
20 mei 2020
Laatste update ingediend die voldeed aan QC-criteria
18 mei 2020
Laatst geverifieerd
1 mei 2020
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- B7921028
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
NEE
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Ja
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Gezond
-
University of LeicesterNational Institute for Health Research, United KingdomVoltooidPatiënten met hartfalen en behouden ejectiefractie - HFpEF | Patiënten met hartfalen met verminderde ejectiefractie - HFrEF | Healthy Controls Group - Leeftijd en geslacht afgestemd
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesBeëindigdZiekte van Parkinson | Healthy Controls Group - Leeftijd en geslacht afgestemdFrankrijk
Klinische onderzoeken op PF-06650833 alone
-
PfizerVoltooid
-
PfizerVoltooid
-
PfizerVoltooid
-
PfizerVoltooidAcne InversaVerenigde Staten, Australië, Canada
-
Yale UniversityPfizerBeëindigd
-
Giovanni Franchin, M.D, Ph.DPfizerWervingCOVID-19 LongontstekingVerenigde Staten
-
PfizerVoltooidReumatoïde artritisTsjechië, Hongarije, Spanje, Polen, Canada, Bulgarije, Chili, Georgië, Slowakije, Oekraïne
-
PfizerVoltooidReumatoïde artritisVerenigde Staten, Korea, republiek van, Spanje, Taiwan, Servië, Georgië, Australië, Hongarije, Tsjechië, Polen, Mexico, Russische Federatie, Bosnië-Herzegovina, Duitsland, Bulgarije, Kroatië, Roemenië, Slowakije, Oekraïne